CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Differential MicroRNA Expression between EGFR T790M and L858R Mutated Lung Cancer
Ji Yeon Kim, Woo Jeong Lee, Ha Young Park, Ahrong Kim, Dong Hoon Shin, Chang Hun Lee
JPTM. 2018;52(5):275-282.   Published online 2018 August 16    DOI:

Excel Download

Differential MicroRNA Expression between EGFR T790M and L858R Mutated Lung Cancer
Journal of Pathology and Translational Medicine. 2018;52(5):275-282   Crossref logo
Link1 Link2 Link3

Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3 -mutation, localized transformation to EGFR -mutated SCLC, and acquired T790M EGFR -mutation
Lung Cancer. 2017;113:14-17   Crossref logo
Link1 Link2

Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report
Lung Cancer. 2017;114:68-69   Crossref logo
Link1 Link2

Impact of coexisting gene mutations in EGFR-mutated non–small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs
Lung Cancer. 2020;139:28-34   Crossref logo
Link1 Link2

Lung Cancer. 2013;80:S13   Crossref logo
Link1 Link2

De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma
Lung Cancer. 2017;114:108-110   Crossref logo
Link1 Link2

Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study
Clinical Lung Cancer. 2018;19(6):e871-e874   Crossref logo
Link1 Link2

Erratum to “Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib” [Lung Cancer, 108 (June 2017) 228–231]
Lung Cancer. 2019;138:141   Crossref logo
Link1 Link2

Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours
Lung Cancer. 2008;60:S3-S9   Crossref logo
Link1 Link2

71: Early experience with osimertinib as second line treatment for EGFR mutated non-small cell lung cancer (NSCLC) and detecting T790M mutations from plasma circulating tumour DNA (ctDNA)
Lung Cancer. 2017;103:S34   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. J Pathol Transl Med has participated in CrossRef Text and Data Mining service since January 16, 2015.